Rituximab (anti-CD20)

Catalog No.A2009 Synonyms: IDEC-C2B8

For research use only.
Not for use in humans.

Rituximab (anti-CD20) is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD.

Rituximab (anti-CD20)

Selleck's Rituximab (anti-CD20) has been cited by 7 Publications

Purity & Quality Control

Choose Selective Immunology & Inflammation related Inhibitors

Biological Activity

Description Rituximab (anti-CD20) is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD.
Targets
CD20 [1]
In vitro

Anti-CD20 IgG1 antibody (rituximab), induces strong antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effects on CD20+ Raji cells with the EC50 at 0.0365 nM and 1.5 nM, respectively.[1]

In vivo

A number of in vivo tumor models suggest the anti-tumor activity of rituximab is dependent, at least in part, on complement[2]. Rituximab can deplete B cells for several months and, as such, could represent an effective therapy for B cell-mediated autoimmune diseases. Rituximab is now widely used in onco-haematology and is currently in development in several autoimmune diseases[3].

Protocol (from reference)

Cell Research:
  • For ADCC experiments, PBMCs were isolated from healthy human donor blood to serve as effector cells and were plated with target Raji cells at E:T ratio of 50:1 in the presence of indicated concentrations of KPL-404, anti-CD20, or isotype antibodies. Target Raji cells were labeled with calcein-AM for detection of cell lysis prior to experimental set up. Following incubation for 4 hours at 37°C in 5% CO2, supernatants from the experiment were analyzed. For CDC experiments, human complement was plated with calcein-AM labeled target Raji cells in the presence of indicated concentrations of KPL-404, anti-CD20, or isotype antibodies. Following incubation for 4 hours at 37°C in 5% CO2, supernatants from the experiment were analyzed.

Animal Research:
  • Objective: To study the mechanisms of follicular lymphoma’s resistance to rituximab
    Animal Models: Female CB17 severe combined immunodeficient(SCID) mice were injected (s.c.) with rituximab-resistant lymphoma cells (derived from a human FL)
    Formulation: --
    Dosages: 10mg/kg, weekly
    Administration: i.p.
    Reference: https://www.ncbi.nlm.nih.gov/pubmed/19188155

    Objective: To investigate the therapeutic effect of rituximab in combination with L19-IL2 on B-cell malignancies
    Animal Models: CB17/lcr severe combined mmunodeficiency (SCID) mice were injected (s.c.) Ramos or DoHH-2 lymphoma cells
    Formulation: saline
    Dosages: 200 μg
    Administration: i.v.
    Reference: https://www.ncbi.nlm.nih.gov/pubmed/19005180

    Rituximab can apply to immunodeficient mice (eg: SCID mice), lymphoma cell lines and other related assays (Only for Reference)

Product Details

CAS No. 174722-31-7
Formulation PBS buffer, pH 7.2
Isotype Human IgG1
Source CHO cells
Storage Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.

Tags: buy Rituximab (anti-CD20) | Rituximab (anti-CD20) supplier | purchase Rituximab (anti-CD20) | Rituximab (anti-CD20) cost | Rituximab (anti-CD20) manufacturer | order Rituximab (anti-CD20) | Rituximab (anti-CD20) distributor